查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968069

全球树突细胞癌症疫苗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Dendritic Cell Cancer Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 112 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

树突状细胞癌疫苗市场预计将从 2025 年的 8.4 亿美元成长到 2034 年的 24.3 亿美元，2026 年至 2034 年的复合年增长率为 12.47%。

随着免疫疗法成为癌症治疗的核心，树突细胞癌疫苗的全球市场正日益受到关注。这些个人化疫苗能够刺激免疫系统更有效地针对癌细胞。癌症发生率的上升和生物技术研究的进步正推动全球对创新疗法的探索。

关键驱动因素包括肿瘤学研究投入的增加、临床试验的扩大以及个人化医疗的普及。支持性的法规结构和细胞疗法的技术进步正在加速产品开发。製药公司与研究机构之间的合作正在加速商业化进程。

随着免疫疗法的突破性进展不断改变癌症治疗的模式，其未来前景仍然光明。生产流程的改进和扩充性的提升可望降低成本并提高可及性。在全球对精准医疗日益关注的背景下，树突细胞疫苗预计将在下一代癌症治疗中发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球树突细胞癌症疫苗市场：依产品划分

  • 市场分析、洞察与预测
  • CreaVax
  • SippleCell-T
  • 其他的

第五章：全球树突细胞癌症疫苗市场：依最终用途划分

  • 市场分析、洞察与预测
  • 儿童
  • 成人

第六章 全球树突细胞癌症疫苗市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Activartis Biotech GmbH
    • Batavia Bioservices BV
    • DanDrit Biotech
    • DCPrime
    • Elios Therapeutics
    • GlaxoSmithKline Plc
    • ImmunoCellular Therapeutics
    • Mendus
    • Northwest Biotherapeutics
    • Sanpower Corporation
简介目录
Product Code: VMR112110152

The Dendritic Cell Cancer Vaccine Market size is expected to reach USD 2.43 Billion in 2034 from USD 0.84 Billion (2025) growing at a CAGR of 12.47% during 2026-2034.

The Global Dendritic Cell Cancer Vaccine Market is gaining traction as immunotherapy becomes a central focus in cancer treatment. These personalized vaccines stimulate the immune system to target cancer cells more effectively. Increasing cancer prevalence and advancements in biotechnology research are driving interest in innovative therapeutic approaches worldwide.

Key drivers include rising investment in oncology research, growing clinical trials, and expanding adoption of personalized medicine. Supportive regulatory frameworks and technological progress in cell-based therapies are enhancing product development. Collaboration between pharmaceutical companies and research institutions is accelerating commercialization efforts.

The future outlook is optimistic as breakthroughs in immunotherapy continue to reshape cancer treatment paradigms. Advancements in manufacturing processes and improved scalability are expected to reduce costs and enhance accessibility. With growing global emphasis on precision medicine, dendritic cell vaccines are projected to play a significant role in next-generation oncology therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

  • CreaVax
  • Sipuleucel-T
  • Others

By End Use

  • Paediatrics
  • Adults

COMPANIES PROFILED

  • Activartis Biotech GmbH, Batavia Bioservices BV, DanDrit Biotech, DCPrime, Elios Therapeutics, GlaxoSmithKline plc, ImmunoCellular Therapeutics, Mendus, Northwest Biotherapeutics, Sanpower Corporation
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET: BY PRODUCT 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. CreaVax Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Sipuleucel-T Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET: BY END USE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast End Use
  • 5.2. Paediatrics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.2.1 By Product
    • 6.2.2 By End Use
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.3.1 By Product
    • 6.3.2 By End Use
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.4.1 By Product
    • 6.4.2 By End Use
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.5.1 By Product
    • 6.5.2 By End Use
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.6.1 By Product
    • 6.6.2 By End Use
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL DENDRITIC CELL CANCER VACCINE INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Activartis Biotech GmbH
    • 8.2.2 Batavia Bioservices B.V
    • 8.2.3 DanDrit Biotech
    • 8.2.4 DCPrime
    • 8.2.5 Elios Therapeutics
    • 8.2.6 GlaxoSmithKline Plc
    • 8.2.7 ImmunoCellular Therapeutics
    • 8.2.8 Mendus
    • 8.2.9 Northwest Biotherapeutics
    • 8.2.10 Sanpower Corporation